爱硒健康网丨广东爱硒健康管理有限公司官网

转移性乳腺癌重磅研究一览

一年一度的全球肿瘤界盛会-美国临床肿瘤学会(ASCO)年会将于当地时间6月3日-6月7日召开。医脉通特梳理了转移性乳腺癌领域的部分重磅研究进展。一起来看下吧!

全体大会

01

摘要号:LBA3

随机III期DESTINY-Breast04研究:T-DXd对比医生选择的治疗方案用于HER2低表达的不可切除和/或转移性乳腺癌患者的疗效

标题:Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

报告人:Shanu Modi, MD

单位:Memorial Sloan Kettering Cancer Center

口头报告

01

摘要号:1000

随机III期DESTINY-Breast03研究:T-DXd对比T-DM1治疗HER2阳性的不可切除和/或转移性乳腺癌患者的的安全性随访

标题:Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

报告人:Erika P. Hamilton, MD

单位:Sarah Cannon Research Institute/Tennessee Oncology

02

摘要号:LBA1001

随机III期TROPiCS-02研究:sacituzumab govitecan(SG)对比医生选择的治疗方案用于激素受体阳性/HER2阴性晚期乳腺癌患者的疗效

标题:Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.

报告人:Hope S. Rugo, MD, FASCO

单位:Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

03

摘要号:1002

Patritumab deruxtecan,HER3靶向抗体偶联药物,治疗HER3表达的转移性乳腺癌患者的I/II期研究结果

标题:Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

报告人:Ian E. Krop, MD, PhD

单位:Dana-Farber Cancer Institute

04

摘要号:LBA1003

PALOMA-2研究:哌柏西利联合来曲唑对比安慰剂联合来曲唑一线治疗ER阳性/HER2阴性晚期乳腺癌患者的总生存

标题:Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

报告人:Richard S. Finn, MD

单位:David Geffen School of Medicine at UCLA

05

摘要号:LBA1004

随机II期MAINTAIN研究:抗雌激素治疗联合CDK4/6抑制剂治疗进展后,氟维司群或依西美坦联合或不联合ribociclib治疗HR阳性,HER2阴性转移性乳腺癌

标题:A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

报告人:Kevin Kalinsky, MD, MS

单位:Winship Cancer Institute, Emory University

06

摘要号:1005

FAKTION研究:芳香化酶抑制剂治疗复发或进展后,氟维司群联合capivasertib对比氟维司群联合安慰剂治疗ER阳性转移性乳腺癌患者的增强生物标志物分析的总生存和更新的无进展生存数据

标题:Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

报告人:Robert Hugh Jones, PhD, FRCP

单位:Velindre Cancer Centre and School of Medicine Cardiff University

07

摘要号:1006

SOLAR-1研究:Alpelisib联合氟维司群治疗HR阳性、HER2阴性晚期乳腺癌患者的NGS生物标志物分析

标题:Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.

报告人:Dejan Juric, MD

单位:Massachusetts General Hospital Cancer Center, Harvard Medical School

08

摘要号:1007

IIR/III期NRG-BR002研究:新发低转移性乳腺癌患者行标准系统治疗联合或不联合立体定向全身放疗(SBRT)和/或手术切除(SR)(NCT02364557)

标题:NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).

报告人:Steven J. Chmura, MD, PhD

单位:The University of Chicago Medicine

09

摘要号:1008

2000-2017年筛查、早期治疗和转移治疗对降低美国女性不同分子亚型乳腺癌死亡率的贡献

标题:Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.

报告人:Jennifer Lee Caswell-Jin, MD, BA

单位:Stanford University

壁报讨论

01

摘要号:1018

海报:396

BYLieve 研究:Alpelisib联合内分泌治疗对HR阳性、HER2阴性、PIK3CA突变的晚期乳腺癌患者的基线生物标志物分析和CDK4/6抑制剂治疗持续时间决定的无进展生存期

标题:Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.

报告人:Dejan Juric, MD

单位:Massachusetts General Hospital Cancer Center, Harvard Medical School

02

摘要号:1022

海报:400

开放标签II期研究:拉索昔芬联合阿贝西利治疗绝经前和绝经后、既往治疗进展后ESR1突变ER阳性/HER2阴性的晚期或转移性乳腺癌女性患者

标题:Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.

报告人:Senthil Damodaran, MD, PhD

单位:The University of Texas MD Anderson Cancer Center

03

摘要号:1023

海报:401

IB/II期研究:BET抑制剂ZEN-3694联合talazoparib治疗无gBRCA1/2突变的TNBC患者的1b/2期研究

标题:A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

报告人:Philippe Georges Aftimos, MD

单位:Institut Jules Bordet, Université Libre de Bruxelles

04

摘要号:1024

海报:402

II期plasmaMATCH研究队列E:奥拉帕利联合ceralasertib治疗三阴性晚期乳腺癌患者(CRUK/15/010)的结果

标题:Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

报告人:Alistair E. Ring, MD, MRCP, MA

单位:The Royal Marsden NHS Foundation Trust

壁报展示

01

摘要号:535

海报:307

绝经后激素受体阳性乳腺癌初始5年辅助内分泌治疗的有效性和安全性:一项系统综述和网络荟萃分析

标题:Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.

报告人:Hao Liao

单位:北京大学肿瘤医院

02

摘要号:539

海报:311

卵巢功能抑制在40岁以上的早期乳腺癌患者中并不是必不可少的

标题:Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.

报告人:Jianqiao Xian, MD

单位:中山大学肿瘤防治中心

03

摘要号:582

海报:353

外周脂质组学分析与集成机器学习预测乳腺癌新辅助治疗的反应

标题:Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.

报告人:王佳妮

单位:中国医学科学院北京协和医学院

04

摘要号:588

海报:359

多中心、单臂、前瞻性II期MUKDEN 01研究初步分析:吡咯替尼联合来曲唑联合达尔西利新辅助治疗三阴性乳腺癌

标题:Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.

报告人:牛楠

单位:中国医科大学附属盛京医院

05

摘要号:TPS618

海报:383b

前瞻性、单臂、开放标签的III期研究:安罗替尼联合替雷利珠单抗和化疗新辅助治疗三阴性乳腺癌

标题:Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.

报告人:罗静

单位:四川省医学科学院·四川省人民医院

06

摘要号:TPS620

海报:384b

单臂II期PILHLE-001研究:吡咯替尼联合表柔比星和环磷酰胺序贯多西他赛新辅助治疗HER低表达,HR阳性早期或局部晚期乳腺癌

标题:Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.

报告人:Yuan Xia

单位:中山大学孙逸仙纪念医院

备注:排名不分先后,按照摘要号进行

加硒教授微信:623296388,送食疗电子书,任选一本

分享到:更多 ()

评论 抢沙发

  • 昵称 (必填)
  • 邮箱 (必填)
  • 网址